Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Toremifene

Next Previous
Drug Profile

Toremifene

Alternative Names: Acapodene®; Fareston; FC 1157; FC 1157a; NK 622; Toremifene citrate

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Orion
  • Developer GTx
  • Class Antineoplastics; Dimethylamines; Phenyl ethers; Small molecules; Stilbenes
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer
  • Discontinued Androgen deprivation therapy complications; Non-small cell lung cancer; Prostatic intraepithelial neoplasia; Renal cancer

Most Recent Events

  • 18 Apr 2016 ProStrakan is now called Kyowa Kirin International
  • 01 Oct 2012 Toremifene is no longer licensed to GTx
  • 01 Oct 2012 Toremifene licensed to ProStrakan in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top